Nodal Mature Plasmacytoid Dendritic Cell Proliferation in a Patient With Chronic Myelomonocytic Leukemia: A Diagnostic Mimic of Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors:
Open Access
- 26 May 2025
- journal article
- case report
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Abstract
Mature plasmacytoid dendritic cell proliferation (MPDCP) is a rare, clonal but nonmalignant entity often associated with myeloid neoplasms such as chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes, and acute myeloid leukemia. While typically confined to the bone marrow, nodal MPDCP is exceedingly rare and may mimic blastic plasmacytoid dendritic cell neoplasm (BPDCN), posing diagnostic challenges. We report a 78-year-old male with CMML-1 and progressive cervical lymphadenopathy. Workup revealed monocytosis, ASXL1 and CBL mutations, and CMML. Lymph node biopsy showed paracortical expansion by small mononuclear cells with plasmacytoid features. Immunophenotyping identified a CD4+, CD123+, CD303+, HLA-DR+, lysozyme+, CD56− population, consistent with MPDCP. A subset expressed TdT and granzyme B, with a Ki-67 index of 20% to 30%. Next-generation sequencing confirmed the same ASXL1 and CBL mutations in the lymph node, supporting clonal relation to CMML. Key differential diagnoses included BPDCN, T-cell lymphomas, Langerhans cell histiocytosis, and Kikuchi–Fujimoto disease. Absence of CD56, mature cytomorphology, and molecular concordance favored MPDCP. This case highlights the importance of distinguishing nodal MPDCP from malignant mimics. MPDCP may reflect immune evasion, altered cytokine signaling, or clonal progression in myeloid neoplasms. The patient was initially treated with hydroxyurea, later transitioned to decitabine/cedazuridine (Inqovi) for disease progression. Follow-up marrow biopsy showed stable CMML-2 with persistent mutations, and the patient remains under close monitoring. Recognizing MPDCP in unusual locations is critical for accurate diagnosis and prognostication. Further studies are warranted to clarify its molecular pathogenesis and potential as a biomarker of disease evolution in CMML and related disorders.Keywords
This publication has 27 references indexed in Scilit:
- Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemiaBlood, 2021
- Blastic plasmacytoid dendritic cell neoplasm. A rare hematodermic malignancyHematology, Transfusion and Cell Therapy, 2020
- Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasmHaematologica, 2020
- How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Blood Advances, 2019
- CD123 as a Therapeutic Target in the Treatment of Hematological MalignanciesCancers, 2019
- Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemiaLeukemia, 2019
- Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasiaHaematologica, 2017
- Neoplasms derived from plasmacytoid dendritic cellsLaboratory Investigation, 2016
- Plasmacytoid Dendritic CellsAdvances in Anatomic Pathology, 2009
- Plasmacytoid dendritic cells in immunityNature Immunology, 2004